Breast Cancer Clinical Trials
|Genentech TDM4370g||A randomized, multicenter, phase 3, open-label study of the efficacy and safety of trastuzumab-MCC-DM1 vs. capecitabine + lapatinib in patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy||Second line after prior taxane and trastuzumab therapy||HER2+, metastatic|
|Celldex CDX011-03||A Phase II, Randomized, Multicenter Study of CDX-011 in Patients with Advanced GPNMB-expressing Breast Cancer||metastatic or recurrent||must have failed a taxane, anthracycline, xeloda (plus herceptin & lapatinib for Her2 + patients)|
|SWOG 0221||Phase III Trial of Continuous Schedule AC + G-CSF vs. Q 2 Week Scehdule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Theapy in Node-Positive or High-Risk Node Negative Breast Cancer||adjuvant||Stage I, II or III (T4 not eligible); must have at least 6 axillary or intramammary lymph nodes sampled with the exception of samples uninvolved sentinel lymph node|
If you have any question on your eligibility for any of these trials or any general questions please feel free to contact our Clinical Research Coordinator at 773-665-6891(P), or fax at 773-665-6890.